[Form 4] ResMed Inc. Insider Trading Activity

Rhea-AI Filing Summary

ResMed Chief Executive Officer Michael J. Farrell exercised stock options and sold shares on 08/07/2025 under a Rule 10b5-1 plan adopted on October 31, 2024. He exercised 8,009 options at a $101.64 exercise price, acquiring 8,009 common shares, and sold those 8,009 shares in multiple trades at a weighted-average price of $279.4829 (individual trades ranged $277.76–$282.66). After the transactions Farrell’s direct beneficial ownership is reported as 455,503 shares, and he also holds 24,029 derivative securities; 2,090 shares are held indirectly via the Lisette and Michael Farrell Family Trust.

Positive

• Transaction executed under a Rule 10b5-1 plan adopted 10/31/2024, indicating pre-arranged trades

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine option exercise followed by a pre-planned sale under a 10b5-1 plan; limited material impact.

The filing shows a contemporaneous exercise of 8,009 options at a $101.64 strike and immediate sale of the same number of shares at a weighted-average price of $279.4829 on 08/07/2025. The sale was executed under a Rule 10b5-1 plan adopted 10/31/2024 and occurred in multiple trades priced $277.76–$282.66. Beneficial ownership moved from 463,512 shares after exercise to 455,503 after sale, leaving the CEO with a substantial remaining direct stake and 24,029 options outstanding. This pattern is consistent with planned option monetization rather than ad hoc insider trading.

Corporate Governance Expert

TL;DR: Proper disclosure and use of a 10b5-1 plan reduce governance concerns; transactions are transparent.

The Form 4 discloses that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted on 10/31/2024, which provides an affirmative defense for trades executed while the insider was not in possession of material nonpublic information. The filing includes exercise details (exercise price $101.64), option exercisability date (11/11/2019), option expiration (11/14/2025), and vesting notes. The clear reporting of weighted-average sale price and trade range improves transparency for shareholders and regulators. Overall, this is a routine, well-documented insider action from a governance standpoint.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	08/07/2025		M(1)		8,009	A	$101.64	463,512	D
ResMed Common Stock	08/07/2025		S(1)		8,009	D	$279.4829(2)	455,503	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	08/07/2025		M			8,009	11/11/2019(3)	11/14/2025	ResMed Common Stock	8,009	$0	24,029	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $277.76 - $282.66. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	Michael J. Farrell, Chief Executive Officer	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ResMed (RMD) CEO Michael J. Farrell do on 08/07/2025?

He exercised 8,009 options at a $101.64 strike and sold 8,009 shares the same day under a Rule 10b5-1 plan.

At what price were the shares sold?

The shares were sold in multiple trades at prices ranging from $277.76 to $282.66, with a weighted-average sale price of $279.4829.

How many shares does Michael J. Farrell own after the transactions?

Following the transactions his reported direct beneficial ownership is 455,503 shares and he beneficially owns 24,029 derivative securities; 2,090 shares are held indirectly in the Lisette and Michael Farrell Family Trust.

Were these trades pre-planned?

Yes. The filing states the transaction was conducted under a Rule 10b5-1 plan adopted on October 31, 2024.

What are the option exercisability and expiration dates disclosed?

The options first became exercisable on 11/11/2019 and have an expiration date of 11/14/2025; options vest 1/3 per year as disclosed.